Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe

DAIICHI SANKYO EUROPE GmbH: Tokyo (ots/PRNewswire) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group (headquartered in Munich, Germany; hereafter, DSE), has granted exclusive rights to …

Das könnte Sie interessieren

German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily LIXIANA® (edoxaban) in NVAF and VTE at ACC’s 65th Annual Scientific Session